Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
Mallinckrodt
Johnson and Johnson
McKinsey

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR FLUTEMETAMOL F-18


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Flutemetamol F-18

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01028053 ↗ Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed i3 Research Phase 3 2009-12-01 This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗ Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed i3 Statprobe Phase 3 2009-12-01 This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
NCT01028053 ↗ Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Completed Medpace, Inc. Phase 3 2009-12-01 This study will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer in identifying abnormal (18F) flutemetamol uptake patterns which predict the conversion from aMCI to a b-amyloid associated clinically probable Alzheimer's disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Flutemetamol F-18

Condition Name

Condition Name for Flutemetamol F-18
Intervention Trials
Alzheimer's Disease 8
Mild Cognitive Impairment 6
Dementia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Flutemetamol F-18
Intervention Trials
Alzheimer Disease 11
Cognitive Dysfunction 8
Cognition Disorders 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Flutemetamol F-18

Trials by Country

Trials by Country for Flutemetamol F-18
Location Trials
United States 10
Switzerland 2
France 2
China 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Flutemetamol F-18
Location Trials
New Jersey 5
Utah 3
New York 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Flutemetamol F-18

Clinical Trial Phase

Clinical Trial Phase for Flutemetamol F-18
Clinical Trial Phase Trials
Phase 4 1
Phase 3 8
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Flutemetamol F-18
Clinical Trial Phase Trials
Completed 7
Terminated 5
Unknown status 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Flutemetamol F-18

Sponsor Name

Sponsor Name for Flutemetamol F-18
Sponsor Trials
GE Healthcare 8
i3 Statprobe 5
University of Utah 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Flutemetamol F-18
Sponsor Trials
Industry 20
Other 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Harvard Business School
Colorcon
Mallinckrodt
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.